Cargando…

First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative

INTRODUCTION: Routine and international comparison of clinical outcomes enabling identification of best practices for patients with pulmonary sarcoidosis is lacking. The aim of this study was to develop a standard set of outcome measures for pulmonary sarcoidosis, using the value-based healthcare pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kampstra, Nynke A, Grutters, Jan C, van Beek, Frouke T, Culver, Daniel A, Baughman, Robert P, Renzoni, Elisabetta A, Wuyts, Wim, Kouranos, Vaslis, Wijsenbeek, Marlies S, Biesma, Douwe H, van der Wees, Philip J, van der Nat, Paul B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Interstitial Lung Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424298/ https://www.ncbi.nlm.nih.gov/pubmed/30956806 http://dx.doi.org/10.1136/bmjresp-2018-000394

Ejemplares similares

Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes
por: Kampstra, Nynke A., et al.
Publicado: (2019)

Outcomes in pulmonary sarcoidosis: results of a newly implemented prednisone protocol
por: Kampstra, Nynke A, et al.
Publicado: (2023)

Patterns of healthcare resource utilization in patients with sarcoidosis: a cross-sectional study
por: Kampstra, Nynke A., et al.
Publicado: (2020)

Needs, Perceptions and Education in Sarcoidosis: A Live Interactive Survey of Patients and Partners
por: Moor, C. C., et al.
Publicado: (2018)

Repository corticotropin for Chronic Pulmonary Sarcoidosis
por: Baughman, Robert P., et al.
Publicado: (2017)

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
por: Maher, Toby M, et al.
Publicado: (2019)

Physical Inactivity in Pulmonary Sarcoidosis
por: Cho, Peter S. P., et al.
Publicado: (2019)

Ranking Self-reported Gastrointestinal Side Effects of Pharmacotherapy in Sarcoidosis
por: Drent, M., et al.
Publicado: (2020)

CASPA (CArdiac Sarcoidosis in PApworth) improving the diagnosis of cardiac involvement in patients with pulmonary sarcoidosis: protocol for a prospective observational cohort study
por: Quijano-Campos, Juan Carlos, et al.
Publicado: (2020)

The Burden of Sarcoidosis Symptoms from a Patient Perspective
por: Voortman, M., et al.
Publicado: (2019)

Psychological burden associated with worse clinical outcomes in sarcoidosis
por: Sharp, Michelle, et al.
Publicado: (2019)

Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome
por: Jacob, Joseph, et al.
Publicado: (2020)

Rationale and design of the SARCoidosis Outcomes in all respiratory Viral Infectious Diseases (SARCOVID) Study
por: Strykowski, Rachel, et al.
Publicado: (2022)

Sarcoidosis and Work Participation: The Need to Develop a Disease-Specific Core Set for Assessment of Work Ability
por: Hendriks, C. M. R., et al.
Publicado: (2019)

Yield of EBUS-TBNA for the diagnosis of sarcoidosis: impact of operator and cytopathologist experience
por: Navasakulpong, Asma, et al.
Publicado: (2016)

Sarcoidosis in the UK: insights from British Thoracic Society registry data
por: Thillai, Muhunthan, et al.
Publicado: (2019)

Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis
por: Kullberg, Susanna, et al.
Publicado: (2021)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
por: Maher, Toby M, et al.
Publicado: (2023)

Gene correlation network analysis to identify regulatory factors in idiopathic pulmonary fibrosis
por: McDonough, John E, et al.
Publicado: (2019)

Identifying causation in hypersensitivity pneumonitis: a British perspective
por: Barber, Christopher Michael, et al.
Publicado: (2019)

Feasibility of investigating methylphenidate for the treatment of sarcoidosis-associated fatigue (the FaST-MP study): a double-blind, parallel-arm randomised feasibility trial
por: Atkins, Christopher, et al.
Publicado: (2021)

The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference
por: Sinha, Aish, et al.
Publicado: (2019)

Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry
por: Wuyts, Wim A, et al.
Publicado: (2018)

Exhaled breath analysis in interstitial lung disease
por: van der Sar, Iris G., et al.
Publicado: (2023)

Hospital-level variation in practices and outcomes for patients with severe acute exacerbations of idiopathic pulmonary fibrosis: a retrospective multicentre cohort study
por: Shankar, Divya A, et al.
Publicado: (2023)

Patients with idiopathic pulmonary fibrosis have poor clinical outcomes with COVID-19 disease: a propensity matched multicentre research network analysis
por: Naqvi, Syeda Fatima, et al.
Publicado: (2021)

In vivo polarisation sensitive optical coherence tomography for fibrosis assessment in interstitial lung disease: a prospective, exploratory, observational study
por: Vaselli, Margherita, et al.
Publicado: (2023)

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
por: Saketkoo, Lesley Ann, et al.
Publicado: (2014)

Diagnostic Performance of Electronic Nose Technology in Sarcoidosis
por: van der Sar, Iris G., et al.
Publicado: (2022)

Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study
por: Troy, Lauren K, et al.
Publicado: (2019)

Utility of radial endobronchial ultrasonography combined with transbronchial lung cryobiopsy in patients with diffuse parenchymal lung diseases: a multicentre prospective study
por: Inomata, Minoru, et al.
Publicado: (2021)

Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study
por: Barratt, Shaney L, et al.
Publicado: (2021)

Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis
por: Dutta, Prosenjit, et al.
Publicado: (2019)

Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients
por: Proesmans, V. L. J., et al.
Publicado: (2019)

Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis
por: McGrath, Emmet E, et al.
Publicado: (2012)

Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
por: Kraven, Luke M, et al.
Publicado: (2023)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2016)

Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)
por: Wild, Jim M, et al.
Publicado: (2021)

TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis
por: Mackintosh, John A, et al.
Publicado: (2021)

CC-90001, a c-Jun N-terminal kinase (JNK) inhibitor, in patients with pulmonary fibrosis: design of a phase 2, randomised, placebo-controlled trial
por: Popmihajlov, Zoran, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_09vl84m8mua7pufgk1acf92cin